Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vapreotide in Pancreas Surgery
NCT00014651Phase 3Terminated
- Sponsor
- Mayo Clinic
- Start
- Mar 2001
- Primary completion
- Mar 2001
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative complications comparing Vapreotide with Placebo (2 arms). Primary endpoint: Postoperative pancreatic complications at 45 days. Started Mar 2001; status: terminated.
02
Drugs
vapreotide
03
Conditions
postoperative complications
Beyond the preview
Go deeper on NCT00014651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014651.